The primary objective of this study is to evaluate the efficacy of 25 mg of psilocybin under supportive conditions to adult participants with BP-II, current episode depressed, in improving depressive symptoms.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Montgomery-Asberg Depression Rating Scale (MADRS)
Timeframe: From Baseline (Day -1) to three weeks post-dose.